Prevention of acute postoperative pressure rises in glaucoma patients undergoing cataract extraction with posterior chamber lens implant

James West, John Burke, Ian Cunliffe, Simon Longstaff

Abstract
Acute elevations in intraocular pressure (IOP) commonly follow extracapsular cataract extraction and lens implant in glaucoma patients. Thirty-six patients with glaucoma undergoing cataract extraction and posterior chamber lens implantation were treated with one of three treatments. Group 1: 500 mg of Diamox sulfaacetamide (acetazolamide) 1 hour preoperatively (10 patients); Group 2: perioperative intracameral Miocrol (acetylcysteine) (11 patients); Group 3: the above treatments combined (15 patients). IOPs were measured at 3, 6, 9, and 24 hours postoperatively. The average of the maximum pressure rises above the preoperative level over the 24-hour period was greatest for the group receiving acetazolamide only at 8.9 mm Hg; for the acetylcysteine group the average maximum rise was 6.3 mm Hg; while the combined treatment group showed a decrease of 0.7 mm Hg. IOP rises of >6 mm Hg were seen in 7% of patients (one of 15) in the combined treatment group, 45% (five of 11) of the acetylcysteine group, and 70% (seven of 10) of the acetazolamide group. IOP rises of >10 mm Hg were seen in 7% of the combined treatment group, in 18% of the acetylcysteine only group, and in 50% of the acetazolamide only group. A pressure rise >20 mm Hg was seen in one patient receiving acetylcysteine only and one patient receiving acetazolamide only. The difference between the acetylcysteine group and the combined group for rises >6 mm Hg was significant using the χ² test while the acetazolamide group showed a significant difference for rises >6 and 10 mm Hg compared with the combined group. All acute pressure rises were recorded before or at 9 hours following operation except in the combined treatment group where the rise occurred at 24 hours. To prevent the acute IOP rises seen following cataract surgery with lens implant in glaucoma patients we recommend combined ocular hypotensive therapy.

Material and methods
Ethical committee approval was obtained prior to commencement of the study.

Patients
Any patient with a diagnosis of open angle glaucoma based on an IOP of more than 21 mm Hg prior to treatment and pathological cupping of the optic disc with visual field loss, undergoing ECCE + IOL surgery, were included in the study following informed consent. Patients with previous intraocular surgery were excluded. None of the patients had undergone previous laser trabeculoplasty. All patients were on some form of topical ocular hypotensive agent, some receiving more than one agent.

Patients were randomly allocated to one of three treatment groups. Group 1: received Diamox sulfaacetamide (acetazolamide) 500 mg orally 1 hour preoperatively; Group 2: received intracameral Miocrol (1:100 solution of acetylcysteine chloride in 3% mannitol) at the end of the operation to refill the anterior chamber; Group 3: received both treatments. Acetazolamide and acetylcysteine were chosen because of their different mechanisms of action, acetazolamide decreasing aqueous production and acetylcysteine increasing aqueous outflow; so in theory, when combined one might expect to see a synergistic effect.

A control group of patients with open angle glaucoma undergoing ECCE + IOL and receiving no treatment to prevent postoperative IOP rises was not included as it was felt unethical to do so considering the previously reported frequency of acute IOP rises in the literature with the consequent risk of such rises for an already compromised optic disc.

Acute IOP rises after ECCE or argon laser trabeculoplasty are well documented. The effectiveness of various ocular hypotensive agents, including carbachol, acetylcysteine, and several β blockers, at reducing the acute IOP rises have been investigated with some encouraging results, but not in patients with pre-existing glaucoma undergoing ECCE + IOL. Because of the lack of research in this important therapeutic area we undertook a study to compare the effectiveness of two agents, with different mechanisms of action, at reducing the acute postoperative IOP rises. Acetazolamide (Diamox) which reduces aqueous production and acetylcysteine (Miocrol) which increases aqueous outflow were used alone or in combination.

Department of Ophthalmology, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF
J West
J Burke
I Cunliffe
S Longstaff
Correspondence to: J West.
Accepted for publication 13 March 1992

British Journal of Ophthalmology 1992; 76: 534–537

Downloaded from http://bjo.bmj.com/ on June 19, 2017 - Published by group.bmj.com
All IOP measurements were observer blind and made at the slit-lamp by means of a standardised application tonometer used for this study only. Preoperative IOPs were taken the day prior to surgery and postoperative readings at 3, 6, 9, and 24 hours following surgery.

Surgery was standardised in all cases to the use of local anaesthesia, corneal section, endocapsular technique, four suture 10/0 nylon closure of the section, and Healonid (sodium hyaluronate) aspiration with a coaxial cannula through the closed section at the end of the procedure.

No complications occurred in any of the surgical procedures and all pupils were adequately dilated. Postoperatively, patients received 2 hourly topical steroid drops and a short acting mydriatic twice daily because of the well known increased risk of uveitis in these patients.

**Results**

A total of 36 patients were recruited overall and Table 1 shows the number of patients in each group with age and sex distribution.

The disease severity as judged by the type and duration of preoperative topical therapy and the preoperative IOP level was very similar for all groups. Timolol was the most commonly used topical ocular hypotensive followed by pilocarpine. No correlation was noted between preoperative ocular hypotensive therapy or the preoperative IOP level in those patients in whom an acute rise in IOP occurred.

Fibrinous uveitis was noted in a few cases within 3 to 6 hours of surgery, and its presence did not correlate with acute IOP rises.

In our results we looked at the maximum IOP elevation above the preoperative level over the 24 hour study period and the time period of the acute rises. These were compared for the patients in each of the three groups.

The majority of maximum postoperative IOPs were less than the preoperative level for each patient in the combined treatment group, while the opposite was true for the single treatment groups. Individual rises or falls for each patient grouped appropriately and in ascending order are shown in Figure 1.

The mean of the maximum IOP rises was +8.9 mm Hg for the acetazolamide group, +6.3 mm Hg for the acetylcholine group and -0.7 mm Hg for the combined treatment group. The differences between the combined group and the single treatment groups proved significant when compared using Student’s t test (0.01>p for acetazolamide vs combined, 0.02>p for acetylcholine vs combined).

Comparing the number and magnitude of IOP rises above the preoperative IOP for each treatment group also showed a marked difference between the combined and the single treatment groups. The differences between the combined group and the acetazolamide group was significant using the χ² test for rises >6 mm Hg (0.001>p) and for rises >10 mm Hg (0.01>p), while the acetylcholine group showed significance for rises >6 mm Hg (0.05>p). Figure 2 summarises these findings. For each measurement time the number of IOP rises >10 mm Hg above the preoperative level in each group are shown in Figure 3. Both single treatment groups had at least one patient with a rise >10 mm Hg at 3, 6, and 9 hours postoperatively while none of the patients in the combined group showed a rise of this magnitude at these measurement times. A greater number of rises above 10 mm Hg occurred at the 3 and 6 hour measurement times compared with the 9 hour measurement time for the acetylcholine group, whereas in the acetazolamide group rises were more numerous at the 6

---

**Table 1 Patient groups**

<table>
<thead>
<tr>
<th></th>
<th>Diamox</th>
<th>Miocohl</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>10</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>Age</td>
<td>78</td>
<td>80</td>
<td>80</td>
</tr>
<tr>
<td>M:F</td>
<td>4:6</td>
<td>3:8</td>
<td>2:13</td>
</tr>
</tbody>
</table>

---

**Graphs:**

- Figure 1: Individual maximum IOP rises above the preoperative level for each patient.
- Figure 2: Number of patients in each group showing IOP rises of >10 mm Hg, >15 mm Hg, and >20 mm Hg over the 24 hour period.
- Figure 3: Number of IOP rises >10 mm Hg recorded at each measurement time for each of the treatment groups.
and 9 hour measurement times. Only one patient at 24 hours postoperatively had a rise >10 mm Hg and this patient was from the combined group.

Discussion

Early postoperative pressure rises within the first 24 hours in eyes undergoing ECCE+IOL are commonly seen and appear to be at maximum by about 6 to 9 hours post surgery.15 17 11 These early pressure rises are seen more commonly (up to 70% in a recent series) and are of great magnitude in patients with open angle glaucoma undergoing ECCE+IOL.

A variety of ocular hypotensive agents have been investigated for their ability to prevent these acute postoperative pressure rises with some encouraging results,14 15 15 but no investigation has taken place in glaucoma patients undergoing ECCE+IOL.

Savage et al8 described worsening of the visual field following ECCE in 9-7% of glaucomatous eyes with severe preoperative field loss (split fixation or central field <10 degrees). The potential hazard of acute postoperative IOP rises in an already severely damaged eye with vulnerable optic nerve was suggested and is further supported by other reports in the literature. Hayreh10 reported 13 cases of anterior ischemic optic neuropathy following cataract surgery, 11 of which had documented postoperative IOP rises; Kolker10 reported loss of central vision in 2/23 (8.7%) eyes with advanced glaucoma undergoing cataract surgery (ICCE); Weinreb11 and Thomas11 have reported marked loss of visual field and central vision in association with a substantial rise in IOP following argon laser trabeculectomy.

Despite antihypertensive treatment acute IOP rises were seen in our patients. However, the combination of both agents proved significantly better at preventing the rises than either agent alone. It is interesting that acetylcholine appeared to perform better than acetazolamide as one would expect the meshwork reserve to be low in most of these patients. For both single treatment groups the greatest number of rises above 10 mm Hg occurred at 6 hours post surgery, and the acute rises above 10 mm Hg in acetylcholine treated patients occurred earlier than those in the acetazolamide treated patients. The only rise of more than 10 mm Hg in the combined treatment group occurred at 24 hours post surgery and it is possible that this rise is an escape phenomenon as one would expect the effects of both drugs to have passed by this time.

Some cases of early fibrinous uveitis were seen at 3 to 6 hours following surgery. However patients with open angle glaucoma, who have been on long term antiglaucoma medication and who are undergoing cataract surgery, are known to be at high risk of developing severe postoperative uveitis irrespective of iris trauma during surgery,15 and none of those patients with an acute postoperative uveitis in this study developed an acute IOP rise.

Another approach to protecting the optic nerve from acute IOP rises is glaucoma triple surgery which has been shown to reduce the frequency and magnitude of early postoperative pressure rises in glaucoma patients.1 16 However the acute IOP rises are not eliminated by this technique. Furthermore, glaucoma triple surgery is associated with a higher postoperative complication rate and a longer period for visual recovery restricting its use in eyes where topical antiglaucoma medication is effective at maintaining IOP control.17-23 For the majority of glaucoma patients who have a preoperatively controlled IOP on medical therapy simple ECCE+IOL is the operation of choice as cataract surgery alone is associated with better long term postoperative IOP control.4 22-24 These patients are at significant risk of developing acute postoperative IOP rises which could cause additional irreversible damage to an already compromised optic disc. An effective means of preventing these acute postoperative IOP rises can only benefit glaucoma patients undergoing ECCE+IOL.

Our findings suggest a combination of preoperative acetazolamide and intracameral acetylcholine, two agents having different and distinct pharmacological effects on aqueous turnover, is the most effective means of preventing such IOP rises.

We thank our colleagues for their help in recruiting patients for our study.

5 Krupin T, Petitt ME, Bishop KJ. Postoperative intraocular pressure rise in open-angle glaucoma patients after cataract or combined cataract-filtration surgery. Ophthalmology 1988; 95: 759-84.
18 Huber C, Remc CH. Lens implantation combined with
Prevention of acute postoperative pressure rises in glaucoma patients undergoing cataract extraction with posterior chamber lens implant

Prevention of acute postoperative pressure rises in glaucoma patients undergoing cataract extraction with posterior chamber lens implant.

J West, J Burke, I Cunliffe and S Longstaff

*Br J Ophthalmol* 1992 76: 534-537
doi: 10.1136/bjo.76.9.534

Updated information and services can be found at: [http://bjo.bmj.com/content/76/9/534](http://bjo.bmj.com/content/76/9/534)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)